Monica Mita, MD
Medical Oncology · San Antonio, TXNPI 1760450043
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $24,423 of the $29,241 with a category attached, or 83.5%. It is spread thinly across 21 manufacturers, the largest accounting for just 21.0%. Reporting peaked in 2020 at $12,664 and has fallen 75.9% since, to $3,051 in 2025.
Across 48 payments — averaging $609.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Boehringer Ingelheim International GmbH$4K
- Sanofi US Services Inc.$4K
- Gilead$4K
- Sanofi$3K
- Athenex Pharmaceutical Division, LLC$2K
- plus $6K from 15 others
Across 343 payments — averaging $15,014 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$3.5M
- Pfizer$535K
- Seagen Inc.$228K
- Tesaro, Inc.$186K
- Incyte Corporation$134K
- Otsuka Pharmaceutical Co., Ltd.$119K
- plus $472K from 20 others
What the payments were for
- Consulting fees$24,42384%
- Speaking & faculty fees$2,5059%
- Travel & lodging$7663%
- Food & beverage$1,5365%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 4 | $6,152 |
| Boehringer Ingelheim International GmbH | 5 | $4,500 |
| Sanofi US Services Inc. | 4 | $3,979 |
| Gilead | 4 | $3,654 |
| Sanofi | 1 | $3,270 |
| Athenex Pharmaceutical Division, LLC | 5 | $2,175 |
| Eisai Inc. | 1 | $1,875 |
| Bayer | 1 | $1,199 |
| Tersera Therapeutics LLC | 3 | $1,182 |
| Pfizer | 2 | $449 |
| Daiichi Sankyo Inc. | 2 | $175 |
| Merck | 5 | $137 |
| Seagen Inc. | 1 | $104 |
| AbbVie | 3 | $99 |
| E.r. Squibb & Sons, L.L.C. | 1 | $63 |
| Novartis | 1 | $60 |
| Tempus AI, Inc | 1 | $45 |
| GE HealthCare | 1 | $41 |
| Puma Biotechnology, Inc. | 1 | $36 |
| Genentech USA, Inc. | 1 | $27 |
| Amgen | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SARCLISA$3,979
- DATROWAY$2,460
- LENVIMA$1,875
- Oral Paclitaxel$1,500
- Encequidar$1,500
- Vitrakvi$1,199
- ZOLADEX$1,157
- Trodelvy$242
- Enhertu$150
- IBRANCE$119
How this compares
$29,241 in reported general payments places this provider in the 75th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 185 | $3,798 |
| Exemestane | 11 | $809 |
| Ibandronate Sodium | 17 | $572 |
| Letrozole | 28 | $410 |
| Gabapentin | 30 | $204 |
| Potassium Chloride | 16 | $187 |
| Prochlorperazine Maleate | 11 | $121 |
| Dexamethasone | 15 | $52 |
| Ondansetron Hcl | 12 | $51 |
| Lorazepam | 12 | $35 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in San Antonio
- Vijay GunugantiSan Antonio$1.5M
- Virginia KaklamaniSan Antonio$787K
- John SarantopoulosSan Antonio$588K
- Sukeshi AroraSan Antonio$188K
- Anthony TolcherSan Antonio$125K
- Zohra NooruddinSan Antonio$113K
- Moshe LevyDallas$5.1M
- Suresh RatnamMcAllen$3M
- Roy HerbstHouston$1.9M
- Andrew WhiteleyDallas$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.